Titre : Lactames macrocycliques

Lactames macrocycliques : Questions médicales fréquentes

Termes MeSH sélectionnés :

Drug Resistant Epilepsy
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Lactames macrocycliques : Questions médicales les plus fréquentes", "headline": "Lactames macrocycliques : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Lactames macrocycliques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-19", "dateModified": "2025-04-15", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Lactames macrocycliques" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Composés macrocycliques", "url": "https://questionsmedicales.fr/mesh/D047028", "about": { "@type": "MedicalCondition", "name": "Composés macrocycliques", "code": { "@type": "MedicalCode", "code": "D047028", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.345" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Maitansine", "alternateName": "Maytansine", "url": "https://questionsmedicales.fr/mesh/D008453", "about": { "@type": "MedicalCondition", "name": "Maitansine", "code": { "@type": "MedicalCode", "code": "D008453", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.345.295.500" } } }, { "@type": "MedicalWebPage", "name": "Rifamycine", "alternateName": "Rifamycins", "url": "https://questionsmedicales.fr/mesh/D012294", "about": { "@type": "MedicalCondition", "name": "Rifamycine", "code": { "@type": "MedicalCode", "code": "D012294", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.345.295.750" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Rifabutine", "alternateName": "Rifabutin", "url": "https://questionsmedicales.fr/mesh/D017828", "about": { "@type": "MedicalCondition", "name": "Rifabutine", "code": { "@type": "MedicalCode", "code": "D017828", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.345.295.750.650" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Streptovarycine", "alternateName": "Streptovaricin", "url": "https://questionsmedicales.fr/mesh/D013310", "about": { "@type": "MedicalCondition", "name": "Streptovarycine", "code": { "@type": "MedicalCode", "code": "D013310", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.345.295.750.650.700" } } } ] }, { "@type": "MedicalWebPage", "name": "Streptovarycine", "alternateName": "Streptovaricin", "url": "https://questionsmedicales.fr/mesh/D013310", "about": { "@type": "MedicalCondition", "name": "Streptovarycine", "code": { "@type": "MedicalCode", "code": "D013310", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.345.295.750.650.700" } } }, { "@type": "MedicalWebPage", "name": "Rifampicine", "alternateName": "Rifampin", "url": "https://questionsmedicales.fr/mesh/D012293", "about": { "@type": "MedicalCondition", "name": "Rifampicine", "code": { "@type": "MedicalCode", "code": "D012293", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.345.295.750.700" } } }, { "@type": "MedicalWebPage", "name": "Rifaximine", "alternateName": "Rifaximin", "url": "https://questionsmedicales.fr/mesh/D000078262", "about": { "@type": "MedicalCondition", "name": "Rifaximine", "code": { "@type": "MedicalCode", "code": "D000078262", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D04.345.295.750.850" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Lactames macrocycliques", "alternateName": "Lactams, Macrocyclic", "code": { "@type": "MedicalCode", "code": "D047029", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Jonathan L Sessler", "url": "https://questionsmedicales.fr/author/Jonathan%20L%20Sessler", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, The University of Texas at Austin, Austin, Texas 78712-1224, United States." } }, { "@type": "Person", "name": "Chunju Li", "url": "https://questionsmedicales.fr/author/Chunju%20Li", "affiliation": { "@type": "Organization", "name": "College of Sciences, Center for Supramolecular Chemistry and Catalysis, Shanghai University, Shanghai, 200444, People's Republic of China. cjli@shu.edu.cn." } }, { "@type": "Person", "name": "Zhongzhen Yang", "url": "https://questionsmedicales.fr/author/Zhongzhen%20Yang", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, University of York, Heslington York YO10 5DD UK William.unsworth@york.ac.uk." } }, { "@type": "Person", "name": "Adrian C Whitwood", "url": "https://questionsmedicales.fr/author/Adrian%20C%20Whitwood", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, University of York, Heslington York YO10 5DD UK William.unsworth@york.ac.uk." } }, { "@type": "Person", "name": "William P Unsworth", "url": "https://questionsmedicales.fr/author/William%20P%20Unsworth", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, University of York, Heslington York YO10 5DD UK William.unsworth@york.ac.uk." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Psychiatric co-morbidity of drug-resistant epilepsy in Veterans.", "datePublished": "2022-12-26", "url": "https://questionsmedicales.fr/article/36577335", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.yebeh.2022.109059" } }, { "@type": "ScholarlyArticle", "name": "Neuromodulation in drug-resistant epilepsy: A review of current knowledge.", "datePublished": "2022-09-05", "url": "https://questionsmedicales.fr/article/36063433", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/ane.13696" } }, { "@type": "ScholarlyArticle", "name": "Risk factors for drug-resistant epilepsy in adult patients.", "datePublished": "2023-04-10", "url": "https://questionsmedicales.fr/article/37045668", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.medcli.2023.03.006" } }, { "@type": "ScholarlyArticle", "name": "Stiripentol add-on therapy for drug-resistant focal epilepsy.", "datePublished": "2022-09-06", "url": "https://questionsmedicales.fr/article/36066395", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/14651858.CD009887.pub6" } }, { "@type": "ScholarlyArticle", "name": "Felbamate add-on therapy for drug-resistant focal epilepsy.", "datePublished": "2022-08-01", "url": "https://questionsmedicales.fr/article/35914010", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/14651858.CD008295.pub6" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés polycycliques", "item": "https://questionsmedicales.fr/mesh/D011083" }, { "@type": "ListItem", "position": 3, "name": "Composés macrocycliques", "item": "https://questionsmedicales.fr/mesh/D047028" }, { "@type": "ListItem", "position": 4, "name": "Lactames macrocycliques", "item": "https://questionsmedicales.fr/mesh/D047029" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Lactames macrocycliques - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Lactames macrocycliques", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-10", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Lactames macrocycliques", "description": "Comment diagnostiquer une infection bactérienne ?\nQuels tests sont utilisés pour les lactames macrocycliques ?\nQuels symptômes indiquent une infection nécessitant des lactames ?\nComment évaluer l'efficacité des lactames macrocycliques ?\nQuels examens d'imagerie sont utiles ?", "url": "https://questionsmedicales.fr/mesh/D047029?mesh_terms=Drug+Resistant+Epilepsy&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Lactames macrocycliques", "description": "Quels sont les symptômes d'une infection bactérienne ?\nLes lactames provoquent-ils des effets secondaires ?\nComment reconnaître une réaction allergique ?\nQuels signes d'infection nécessitent une attention médicale ?\nLes lactames macrocycliques affectent-ils le système digestif ?", "url": "https://questionsmedicales.fr/mesh/D047029?mesh_terms=Drug+Resistant+Epilepsy&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Lactames macrocycliques", "description": "Comment prévenir les infections bactériennes ?\nLes lactames macrocycliques sont-ils utilisés en prophylaxie ?\nQuelles mesures d'hygiène sont recommandées ?\nLes vaccinations aident-elles contre les infections ?\nComment éviter la résistance aux antibiotiques ?", "url": "https://questionsmedicales.fr/mesh/D047029?mesh_terms=Drug+Resistant+Epilepsy&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Lactames macrocycliques", "description": "Comment les lactames macrocycliques sont-ils administrés ?\nQuel est le mécanisme d'action des lactames ?\nCombien de temps dure un traitement typique ?\nQuels antibiotiques sont des lactames macrocycliques ?\nComment gérer les effets secondaires des lactames ?", "url": "https://questionsmedicales.fr/mesh/D047029?mesh_terms=Drug+Resistant+Epilepsy&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Lactames macrocycliques", "description": "Quelles complications peuvent survenir avec les lactames ?\nComment gérer une surinfection ?\nLes lactames peuvent-ils causer des troubles rénaux ?\nQuels sont les signes d'une réaction sévère ?\nLes lactames macrocycliques peuvent-ils interagir avec d'autres médicaments ?", "url": "https://questionsmedicales.fr/mesh/D047029?mesh_terms=Drug+Resistant+Epilepsy&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Lactames macrocycliques", "description": "Quels facteurs augmentent le risque d'infection ?\nLes antécédents d'allergies influencent-ils le traitement ?\nLe mode de vie affecte-t-il le risque d'infection ?\nLes personnes âgées sont-elles plus à risque ?\nLes voyages augmentent-ils le risque d'infections ?", "url": "https://questionsmedicales.fr/mesh/D047029?mesh_terms=Drug+Resistant+Epilepsy&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une infection bactérienne ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des cultures bactériennes et des tests de sensibilité." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour les lactames macrocycliques ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de sensibilité aux antibiotiques sont effectués pour évaluer l'efficacité." } }, { "@type": "Question", "name": "Quels symptômes indiquent une infection nécessitant des lactames ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre, douleur, inflammation et signes d'infection localisée peuvent indiquer une infection." } }, { "@type": "Question", "name": "Comment évaluer l'efficacité des lactames macrocycliques ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité est évaluée par l'amélioration clinique et la réduction des cultures positives." } }, { "@type": "Question", "name": "Quels examens d'imagerie sont utiles ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des radiographies ou IRM peuvent être utilisées pour évaluer des infections profondes." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une infection bactérienne ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre, frissons, douleur, rougeur et gonflement au site d'infection sont fréquents." } }, { "@type": "Question", "name": "Les lactames provoquent-ils des effets secondaires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets secondaires comme des éruptions cutanées ou des troubles gastro-intestinaux peuvent survenir." } }, { "@type": "Question", "name": "Comment reconnaître une réaction allergique ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des démangeaisons, un gonflement ou des difficultés respiratoires peuvent indiquer une allergie." } }, { "@type": "Question", "name": "Quels signes d'infection nécessitent une attention médicale ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Une fièvre élevée persistante ou des douleurs intenses doivent être évaluées par un médecin." } }, { "@type": "Question", "name": "Les lactames macrocycliques affectent-ils le système digestif ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent causer des nausées, vomissements ou diarrhées chez certains patients." } }, { "@type": "Question", "name": "Comment prévenir les infections bactériennes ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une bonne hygiène, des vaccinations et un usage prudent des antibiotiques aident à prévenir." } }, { "@type": "Question", "name": "Les lactames macrocycliques sont-ils utilisés en prophylaxie ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent être utilisés en prophylaxie pour prévenir des infections post-chirurgicales." } }, { "@type": "Question", "name": "Quelles mesures d'hygiène sont recommandées ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Se laver les mains régulièrement et éviter le contact avec des personnes malades sont essentiels." } }, { "@type": "Question", "name": "Les vaccinations aident-elles contre les infections ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines vaccinations peuvent réduire le risque d'infections bactériennes spécifiques." } }, { "@type": "Question", "name": "Comment éviter la résistance aux antibiotiques ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser les antibiotiques uniquement lorsque nécessaire et suivre les prescriptions médicales." } }, { "@type": "Question", "name": "Comment les lactames macrocycliques sont-ils administrés ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent être administrés par voie intraveineuse ou orale, selon l'infection." } }, { "@type": "Question", "name": "Quel est le mécanisme d'action des lactames ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Ils inhibent la synthèse de la paroi cellulaire bactérienne, entraînant la mort des bactéries." } }, { "@type": "Question", "name": "Combien de temps dure un traitement typique ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La durée du traitement varie, mais elle est généralement de 7 à 14 jours selon l'infection." } }, { "@type": "Question", "name": "Quels antibiotiques sont des lactames macrocycliques ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des exemples incluent la méropénème et l'imipénème, utilisés pour des infections graves." } }, { "@type": "Question", "name": "Comment gérer les effets secondaires des lactames ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Il est important de signaler tout effet indésirable au médecin pour ajuster le traitement." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les lactames ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des réactions allergiques graves ou des infections secondaires peuvent survenir." } }, { "@type": "Question", "name": "Comment gérer une surinfection ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Une évaluation médicale est nécessaire pour ajuster le traitement et cibler la nouvelle infection." } }, { "@type": "Question", "name": "Les lactames peuvent-ils causer des troubles rénaux ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains lactames peuvent affecter la fonction rénale, nécessitant une surveillance." } }, { "@type": "Question", "name": "Quels sont les signes d'une réaction sévère ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme des difficultés respiratoires ou un gonflement du visage nécessitent une urgence." } }, { "@type": "Question", "name": "Les lactames macrocycliques peuvent-ils interagir avec d'autres médicaments ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent interagir avec d'autres médicaments, il est donc important d'informer le médecin." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque d'infection ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'immunodépression, le diabète et les interventions chirurgicales augmentent le risque." } }, { "@type": "Question", "name": "Les antécédents d'allergies influencent-ils le traitement ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents d'allergies aux antibiotiques peuvent limiter les options de traitement." } }, { "@type": "Question", "name": "Le mode de vie affecte-t-il le risque d'infection ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque." } }, { "@type": "Question", "name": "Les personnes âgées sont-elles plus à risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées ont un système immunitaire affaibli, les rendant plus vulnérables." } }, { "@type": "Question", "name": "Les voyages augmentent-ils le risque d'infections ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les voyages peuvent exposer à des agents pathogènes inconnus, augmentant le risque d'infection." } } ] } ] }

Sources (10000 au total)

Psychiatric co-morbidity of drug-resistant epilepsy in Veterans.

Psychiatric conditions are frequently co-morbid in epilepsy and studies examining Veterans with epilepsy suggest this population may present with unique psychiatric and clinical features Drug-resistan... Psychiatric and hospitalization data were collected on 52,579 Veterans enrolled in VHA healthcare between FY2014-2ndQtr.FY2020 from the VHA Corporate Data Warehouse administrative data. Data examined ... At least one psychiatric diagnosis was present in 70.2% of patients, while 49.8% had two or more diagnoses. Depression (51.7%), posttraumatic stress disorder (PTSD) (38.8%), and anxiety (38.0%) repres... A substantial psychiatric burden exists among Veterans with DRE. Compared to prior epilepsy literature, results suggest that Veterans with DRE evidence more prevalent psychiatric comorbidity, emergenc...

Risk factors for drug-resistant epilepsy in adult patients.

Drug-resistant epilepsy occurs in about 30% of epilepsy patients. It has been suggested that etiology or seizure type would increase the risk of pharmacoresistance. This study aims to compare the char... A multicentric cohort study was conducted between 2019 and 2022. We included patients >18 years-old with epilepsy but excluded psychogenic non-epileptic seizures and less than 2 years of follow-up.... We included 128 patients, of whom 46 had drug-resistance epilepsy, and 82 responding to medication. Both groups showed similar characteristics. Febrile seizures (OR: 7.25), focal epilepsy (OR: 2.4), f... Following other studies, we observed that factors such as epilepsy type, seizure type, structural etiology, abnormal MRI, and febrile seizure increased the risk for drug-resistance epilepsy, in our po...

Stiripentol add-on therapy for drug-resistant focal epilepsy.

This is an updated version of the Cochrane Review first published in 2014 and last updated in 2020. For nearly 30% of people with epilepsy, current treatments do not control seizures. Stiripentol is a... To evaluate the efficacy and tolerability of stiripentol as add-on treatment for people with drug-resistant focal epilepsy who are taking AEDs.... For the latest update, we searched the Cochrane Register of Studies (CRS Web) and MEDLINE on 28 March 2022. We contacted the manufacturer of stiripentol and epilepsy experts to identify published, unp... Randomised controlled trials of add-on stiripentol in people with drug-resistant focal epilepsy.... Review authors independently selected trials for inclusion and extracted data. We investigated outcomes including 50% or greater reduction in seizure frequency, seizure freedom, adverse effects, treat... On the basis of our selection criteria, we included no new studies in the present review update. We included only one study from the original review (32 children with focal epilepsy). This study adopt... We have found no new studies since the last version of this review was published. Hence, we have made no changes to the conclusions as presented in previous versions. We can draw no conclusions to sup...

Felbamate add-on therapy for drug-resistant focal epilepsy.

This is an updated version of the Cochrane Review first published in 2011, and most recently updated in 2019. Epilepsy is a chronic and disabling neurological disorder, affecting approximately 1% of t... To evaluate the efficacy and tolerability of felbamate versus placebo when used as an add-on treatment for people with drug-resistant focal-onset epilepsy.... For the latest update, we searched the Cochrane Register of Studies (CRS Web) and MEDLINE (Ovid, 1946 to 13 July 2021) on 15 July 2021. There were no language or time restrictions. We reviewed the ref... We searched for randomised placebo-controlled add-on studies of people of any age with drug-resistant focal seizures. The studies could be double-blind, single-blind or unblinded and could be of paral... Two review authors independently selected studies for inclusion and extracted information. In the case of disagreements, a third review author arbitrated. Review authors assessed the following outcome... We included four randomised controlled trials, representing a total of 236 participants, in the review. Two trials had parallel-group design, the third had a two-period cross-over design, and the four... In view of the methodological deficiencies, the limited number of included studies and the differences in outcome measures, we have found no reliable evidence to support the use of felbamate as an add...

Association of intracranial abnormalities with the development of epilepsy and drug-resistant epilepsy in patients with Parry-Romberg syndrome.

Epilepsy represents an essential component of Parry Romberg syndrome (PRS). This study aimed to identify clinical factors that influence the development of epilepsy and drug-resistant epilepsy (DRE) i... We retrospectively reviewed the medical records of eighty patients with PRS. Data including the age of onset for PRS, history of seizures, use and timing of immunotherapy, antiseizure medication use, ... Eighteen (22.5%) had epilepsy: 12 were female, and the median age was 14.5 years (range = 6-48 years). Eleven patients developed DRE. The median latency between the onset of cutaneous manifestations a... The presence and degree of severity of ipsilateral brain abnormalities are risk factors for the development of epilepsy in PRS but not factors in predicting drug resistance. The timing of immunotherap...